Revenue from Moderna's COVID vaccine will continue for the foreseeable future. Moderna has a deep pipeline with several ...
Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial after showing positive results in an earlier study. The biotech company is hoping its ...
The CDC panel's vote comes after the FDA approved and authorized the new shots from Moderna and Pfizer on Monday, amid an increase in COVID hospitalizations and concern about the spread of several ...
A small percentage of Americans got the most recent covid-19 booster shot, and even fewer probably realize the federal government is preparing to recommend yet another shot as early as Tuesday. This ...
At the recommendation of the FDA, the new boosters protect against XBB variants, which made up 95% of all U.S. Covid cases in June.
U.S. regulators on Tuesday authorized another option for fall COVID-19 vaccination, updated shots made by Novavax. Updated vaccines from Pfizer and Moderna began rolling out last month, intended for ...
A small percentage of Americans got the most recent COVID-19 booster shot, and even fewer probably realize the federal government is preparing to recommend yet another shot as early as Tuesday.
A small percentage of Americans got the most recent COVID-19 booster shot, and even fewer probably realize the federal government is preparing to recommend yet another shot as early as Tuesday.
Moderna has pledged never to enforce its coronavirus vaccine patents in selected low- and middle-income countries and is launching a new initiative to give external researchers access to its ...
Your article was successfully shared with the contacts you provided. Credit: OleksSH/Shutterstock A small percentage of Americans got the most recent COVID-19 booster shot, and even fewer probably ...
A small percentage of Americans got the most recent COVID-19 booster shot, and even fewer probably realize the federal government is preparing to recommend yet another shot as early as Tuesday.
Moderna CEO Stéphane Bancel told investors in August that the company expected its global COVID vaccine sales to be $6 billion to $8 billion this year, depending on uptake in the U.S. Pfizer ...
